Prostanoids in the therapy of glaucoma

Area of Science:

• Ophthalmology
• Pharmacology
• Glaucoma Research

Background:

• Elevated intraocular pressure (IOP) is a primary risk factor for glaucoma, a progressive optic neuropathy.
• Lowering IOP is the sole therapeutic strategy for glaucoma management.
• Historical development of glaucoma treatments has focused on discovering potent, long-lasting, and safe IOP-lowering drugs.

Purpose of the Study:

• To review the development and efficacy of prostanoids as glaucoma medications.
• To highlight the advantages of prostanoids over older treatments like beta-adrenoceptor antagonists.
• To introduce tafluprost as a new FP-receptor agonist in clinical development.

Main Methods:

• Literature review of glaucoma treatment development.
• Analysis of clinical data on prostanoid efficacy and safety.
• Comparison of prostanoids with other ocular antihypertensive drugs.

Main Results:

• Prostanoids, acting as FP-receptor agonists, are potent IOP-lowering agents.
• Three prostanoids (latanoprost, travoprost, bimatoprost) are established treatments.
• Tafluprost is a new prostanoid candidate with potential benefits, including improved ocular blood flow.
• Prostanoids demonstrate superior IOP-lowering efficacy and favorable safety profiles compared to beta-blockers.

Conclusions:

• Prostanoids are the current first-line therapy for ocular hypertension and glaucoma.
• Their efficacy, safety, patient compliance, and cost-effectiveness make them superior to other treatments.
• Tafluprost represents a promising advancement in prostanoid-based glaucoma therapy.